International journal of clinical oncology · 2026
Clinical effectiveness of intra-arterial chemoradiotherapy for advanced maxillary sinus carcinoma: based on the reports of the head and neck cancer registry of Japan.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hemmi Masahiro, Sano Daisuke, Kawakita Daisuke, Yoshimoto Seiichi, Kitayama Megumi, Nibu Ken-Ichi, Oridate Nobuhiko
Аннотация
BACKGROUND: Based on the results of the JCOG1212 trial, superselective intra-arterial infusion chemoradiotherapy (IA-CRT) has become a standard treatment option for patients with locally advanced maxillary sinus carcinoma (LA-MSC), especially those with T4a disease, in Japan. This study aimed to evaluate the real-world effectiveness of IA-CRT compared with systemic intravenous chemoradiotherapy (IV-CRT) in patients with LA-MSC.
METHODS: We retrospectively analyzed data from patients with T3 and T4 N0M0 maxillary sinus carcinoma who were treated with IA-CRT or IV-CRT between 2011 and 2017, using data from the Head and Neck Cancer Registry of Japan. The primary endpoint was the 5-year local control rate (LCR), and the secondary endpoints were overall survival (OS) and progression-free survival (PFS). Survival analyses were performed using inverse probability of treatment weighting (IPTW) adjustment.
RESULTS: Among 1,329 registered patients, 507 received definitive chemoradiotherapy as initial treatment, including 373 patients treated with IA-CRT (median follow-up, 46 months) and 134 treated with IV-CRT (median follow-up, 31 months). After IPTW adjustment, the 5-year LCR was significantly higher in the IA-CRT group than in the IV-CRT group (67.0% vs. 46.0%; hazard ratio, 0.61; 95% confidence interval, 0.44-0.84; p = 0.0023). OS and PFS showed no significant differences between the two groups.
CONCLUSIONS: IA-CRT was associated with improved local control compared with IV-CRT in patients with LA-MSC. Although its impact on survival outcomes remains uncertain, these findings provide real-world evidence that complements the results of the JCOG1212 trial and inform treatment selection in routine clinical practice.
METHODS: We retrospectively analyzed data from patients with T3 and T4 N0M0 maxillary sinus carcinoma who were treated with IA-CRT or IV-CRT between 2011 and 2017, using data from the Head and Neck Cancer Registry of Japan. The primary endpoint was the 5-year local control rate (LCR), and the secondary endpoints were overall survival (OS) and progression-free survival (PFS). Survival analyses were performed using inverse probability of treatment weighting (IPTW) adjustment.
RESULTS: Among 1,329 registered patients, 507 received definitive chemoradiotherapy as initial treatment, including 373 patients treated with IA-CRT (median follow-up, 46 months) and 134 treated with IV-CRT (median follow-up, 31 months). After IPTW adjustment, the 5-year LCR was significantly higher in the IA-CRT group than in the IV-CRT group (67.0% vs. 46.0%; hazard ratio, 0.61; 95% confidence interval, 0.44-0.84; p = 0.0023). OS and PFS showed no significant differences between the two groups.
CONCLUSIONS: IA-CRT was associated with improved local control compared with IV-CRT in patients with LA-MSC. Although its impact on survival outcomes remains uncertain, these findings provide real-world evidence that complements the results of the JCOG1212 trial and inform treatment selection in routine clinical practice.